Can Weight-Loss Drugs Treat Addiction? What the Research Says About GLP-1 Medications
If you've been on social media, watched the news, or talked to your doctor in the last few years, you've heard of GLP-1 medications like Ozempic, Wegovy, and Mounjaro. They were built to treat diabetes and obesity — but a strange thing kept happening in the background. Patients taking them for weight loss started mentioning, almost as an aside, that they'd also lost interest in drinking. Or smoking. Or the nightly glass of wine that used to turn into three.
That anecdotal pattern has since become one of the more closely watched questions in psychiatry and addiction medicine: can a medication designed to regulate blood sugar and appetite actually change how the brain responds to alcohol, nicotine, and other addictive substances?
The short answer is: the evidence — especially for alcohol — is stronger than most people realize, but the field is still young, and these medications are not yet an approved treatment for any addiction. Below, we walk through what the research actually shows, how these drugs may work on the brain's reward system, and what a realistic, honest conversation about this option looks like today.
A note before we start: GLP-1 medications are not currently FDA-approved for treating alcohol use disorder, nicotine dependence, or opioid use disorder. Any use for these purposes is considered off-label, meaning it's based on a physician's clinical judgment and the emerging evidence described here — not on an approved indication. This article is educational, not a recommendation for or against any specific treatment.
How GLP-1 Drugs Ended Up in an Addiction Conversation
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after you eat. It signals your pancreas to release insulin, slows digestion, and tells your brain you're full. Medications like semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon) are synthetic versions of this hormone, engineered to last longer in the body so they can be taken weekly instead of being broken down in minutes.
What's turned out to be scientifically interesting is that GLP-1 doesn't just act in the gut. Receptors for it are scattered throughout brain regions tied to mood, motivation, and reward — including the ventral tegmental area and nucleus accumbens, the same circuitry involved in cravings and substance use. Preclinical research in animals has shown fairly consistently that activating these receptors reduces alcohol-seeking, nicotine-seeking, and in some models, cocaine- and opioid-seeking behavior, largely by dampening dopamine release in reward pathways.
That laboratory groundwork is part of why, when a wave of patients on GLP-1 drugs started reporting less interest in alcohol, researchers weren't entirely surprised. It gave the anecdotes a plausible biological story.
The Evidence for Alcohol Use Disorder: The Strongest Signal So Far
Alcohol use disorder (AUD) is where the human data is furthest along, and it's worth walking through the actual studies rather than just the headlines.
The largest randomized trial to date. A 26-week, double-blind, placebo-controlled trial published in The Lancet in 2026 followed 108 adults with moderate-to-severe alcohol use disorder and co-occurring obesity. Participants were randomly assigned to weekly semaglutide (2.4 mg, the same dose used for weight management) or placebo, both alongside standard cognitive behavioral therapy. The semaglutide group showed a significantly greater reduction in heavy drinking days than the placebo group, along with meaningful drops in total alcohol consumed, drinks per drinking day, and self-reported cravings. Blood biomarkers that objectively track recent alcohol intake improved as well, which matters because it means the results weren't just people under-reporting their drinking to please researchers.
A second, independent randomized trial published in JAMA Psychiatry in 2025 tested lower-dose semaglutide in adults with alcohol use disorder who weren't necessarily trying to quit. It found reduced alcohol intake during a supervised drinking task, fewer drinks per drinking day, and lower weekly cravings compared to placebo.
Larger, real-world data tell a similar story. A retrospective study of over 80,000 patients with obesity, published in Nature Communications, found that those prescribed semaglutide had roughly a 50–56% lower risk of a new or repeat alcohol use disorder diagnosis compared to patients on other anti-obesity medications. A separate Swedish national cohort study following more than 225,000 people with alcohol use disorder for close to nine years found that both semaglutide and liraglutide were associated with meaningfully lower rates of alcohol-related hospitalization, with semaglutide showing the strongest association.
Meta-analyses pooling this evidence — combining randomized trials with observational studies — have generally found consistent reductions in AUDIT scores (a standard alcohol-use screening measure), drinking days, and alcohol-related medical events across the GLP-1 drug class, though the size of the effect varies by which specific medication is used and how it's studied.
Not every trial has been positive. An earlier study of once-weekly exenatide in 127 patients with alcohol use disorder did not find an overall difference in heavy drinking days compared to placebo — though a subgroup of participants with obesity did show benefit, along with reduced brain activity in reward-related regions when shown alcohol-related cues on functional MRI. That pattern — benefit that shows up more clearly in people who also have obesity or metabolic disease — has come up often enough across studies that several researchers now think it may be a real signal, not a coincidence.
What About Nicotine, Opioids, and Other Substances?
This is where it's important to be honest that the evidence thins out considerably.
Nicotine and smoking. Results have been mixed. One 12-week trial of dulaglutide added to standard smoking-cessation therapy (varenicline plus counseling) found no significant improvement in smoking abstinence rates compared to placebo — but a secondary analysis of that same trial did find a meaningful reduction in alcohol consumption among participants, which is part of how researchers first noticed the alcohol-specific effect. A separate pilot trial combining exenatide with nicotine replacement therapy did show improved abstinence rates and reduced post-cessation weight gain. Overall, nicotine looks like a much weaker and less consistent target than alcohol at this point.
Opioids. Human clinical data here is essentially absent — most of what we know comes from preclinical (animal) research. Liraglutide has shown fairly consistent reductions in heroin-seeking behavior across multiple rodent studies, including during stress-induced relapse scenarios, without affecting normal reward-seeking (like interest in food). One brain-imaging study in humans using fentanyl-related cues found some suggestive changes in brain response with liraglutide, but this line of research is still in its early stages and far from clinical application.
Cocaine and stimulants. This is the substance category with the most inconsistent findings. Some preclinical studies show GLP-1 drugs reducing cocaine-seeking behavior in animals through effects on dopamine and glutamate signaling in reward circuits. But the one human trial testing exenatide in cocaine use disorder found no significant effect on cocaine use, craving, or euphoria compared to placebo, in a small, single-dose study.
The broader picture. A 2026 systematic review in Frontiers in Pharmacology, which pooled 42 studies across alcohol, nicotine, cocaine, and opioid research, concluded that preclinical evidence for GLP-1 drugs reducing substance-seeking behavior is strong and fairly consistent across substance types — but clinical (human) evidence remains sparse outside of alcohol, and is limited by small sample sizes and short study durations.
In plain terms: alcohol has the best human evidence by a wide margin. Everything else is either preliminary, mixed, or still confined to animal studies.
Why Might This Work? The Leading Theories
Researchers have proposed a few overlapping mechanisms, and it's likely more than one is at play:
Dopamine and reward dampening. GLP-1 receptors sit directly in brain circuits that release dopamine in response to rewarding experiences, including alcohol and drugs. Activating these receptors appears to blunt that dopamine surge, which may translate to a substance simply feeling less rewarding or less "worth it."
Reduced cue reactivity. Brain imaging studies have found that people treated with GLP-1 drugs show less activation in reward-related brain regions when shown pictures or cues related to alcohol, compared to before treatment — suggesting the cravings themselves may be quieter.
Appetite and satiety crossover. Because these drugs slow digestion and increase feelings of fullness, some researchers believe there's a physical component too — after a drink or two, patients report feeling fuller and less inclined to keep drinking.
Metabolic and psychological reinforcement. Weight loss and improved metabolic health seem to reinforce healthier behavior more broadly, which may support reduced substance use indirectly, alongside the direct neurological effects.
None of these explanations are fully settled, and most researchers now think the real story involves an overlap between the metabolic and reward-related effects of these drugs, rather than one single mechanism.
What's Still Uncertain
It's worth being direct about the open questions, because they matter for anyone considering this option:
Not FDA-approved for addiction. As of now, GLP-1 medications are approved only for diabetes, weight management, sleep apnea, and certain cardiovascular indications — not for any substance use disorder. Prescribing them for alcohol or nicotine use is off-label.
Phase 3 trials are underway. Several larger, purpose-built trials evaluating GLP-1 drugs specifically for alcohol use disorder, opioid use disorder, and other psychiatric conditions are in progress, with results expected over the next one to three years. These will be far more definitive than what we have today.
Not everyone responds. Even in the positive alcohol trials, a meaningful subset of participants showed little or no reduction in drinking, even at the highest doses — similar to the "non-responder" pattern seen in weight-loss trials for these same drugs.
The benefit may fade after stopping. As with weight loss, there's some evidence that reduced drinking or substance use can return toward baseline levels if the medication is discontinued, which raises questions about whether this needs to be a long-term commitment rather than a short course.
Side effects are real, though usually manageable. Nausea, constipation, decreased appetite, and gastrointestinal discomfort are common, especially when starting or increasing the dose. These are typically mild-to-moderate and improve over time, but they lead some patients to stop the medication.
Psychiatric safety monitoring continues. Early pharmacovigilance reports flagged possible links between GLP-1 drugs and mood changes or suicidal thoughts. Since then, larger, better-controlled studies — including a large UK cohort study of over 370,000 patients — have not found an increased risk of suicidality associated with these medications, even among patients with a prior history of depression or self-harm. Still, ongoing monitoring is standard practice, and anyone with a personal or family psychiatric history should discuss this directly with their prescriber.
Cost and access. These medications remain expensive, often $800–$1,300 a month without insurance, and insurance coverage for an off-label use like addiction is inconsistent at best.
Who Might Be a Reasonable Candidate?
Based on where the evidence currently stands, GLP-1 medications appear most relevant for adults who:
Have alcohol use disorder and a co-occurring condition like obesity or type 2 diabetes, where the medication is already a reasonable option for the metabolic condition
Have tried first-line, FDA-approved treatments for alcohol use disorder (like naltrexone, acamprosate, or disulfiram) without adequate success, or couldn't tolerate them
Are looking for a harm-reduction approach — meaningfully cutting back drinking — rather than requiring total abstinence as the only measure of success
Are prepared for ongoing treatment and monitoring, rather than viewing this as a quick fix
This is very much an individualized decision, not a blanket recommendation, and it's not a replacement for therapy, structured alcohol treatment programs, or FDA-approved medications where those are working.
What a Conversation About This Might Look Like
If you're curious whether this approach could fit your situation, a thoughtful evaluation typically includes:
A full review of your alcohol or substance use history, prior treatment attempts, and any co-occurring medical or psychiatric conditions
A discussion of FDA-approved options first, and why they have or haven't worked for you
An honest conversation about what's known and unknown about GLP-1 medications for this purpose, including realistic expectations
Screening for any conditions that would make these medications inappropriate (such as a personal or family history of certain thyroid cancers, or pancreatitis)
A plan for monitoring — both for effectiveness and for side effects — if you decide to move forward
Dr. Memon stays closely engaged with this rapidly evolving area of research and is glad to have this conversation directly with patients who are exploring whether an off-label approach like this makes sense as part of a broader, individualized treatment plan alongside therapy and other evidence-based care.
The Bottom Line
The idea that a diabetes and weight-loss drug might also help with alcohol use disorder sounds almost too tidy to be true — but the human evidence, particularly two independent randomized controlled trials plus multiple large real-world studies, makes a genuinely compelling case that something real is happening for at least some patients. Nicotine and opioid evidence is far earlier-stage and shouldn't be oversold. And even for alcohol, this isn't a cure, an approved treatment, or a substitute for comprehensive, individualized care — it's an emerging option worth an honest conversation with a psychiatrist who's paying close attention to where the research is heading.
If you're struggling with alcohol use, or you're curious whether this kind of approach fits your specific situation, schedule a consultation to talk it through — no assumptions, just an honest look at what might actually help.
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for a professional evaluation by a qualified healthcare provider. Always consult a licensed physician before starting, stopping, or changing any medication or treatment plan.